October 1st 2024
Your daily dose of the clinical news you may have missed.
September 18th 2024
EASD 2024: Amycretin was also found to be safe and well tolerated in adults with obesity and without diabetes.
September 16th 2024
September 11th 2024
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
September 3rd 2024